Introduction: Hyperbaric oxygenation (HBO), in addition to anti-infective and surgical therapy, seems to be a key treatment point for Fournier’s gangrene. The aim of this study was to investigate the influence of HBO therapy on the outcome and prognosis of Fournier’s gangrene. Patients and Methods: In the present multicenter, retrospective observational study, we evaluated the data of approximately 62 patients diagnosed with Fournier’s gangrene between 2007 and 2017. For comparison, 2 groups were distinguished: patients without HBO therapy (group A, n = 45) and patients with HBO therapy (group B, n = 17). The analysis included sex, age, comorbidities, clinical symptoms, laboratory and microbiological data, debridement frequency, wound dressing, antibiotic use, outcome and prognosis. The statistical analysis was performed with GraphPad Prism 7® (GraphPad Software, Inc., La Jolla, USA). Results: Demographic data showed no significant differences. The laboratory parameters C-reactive protein and urea were significantly higher in group B (group B: 301.7 vs. 140.6 mg/dL; group A: 124.8 vs. 54.7 mg/dL). Sepsis criteria were fulfilled in 77.8 and 100% of the patients in groups A and B respectively. Treatment in the intensive care unit (ICU) was therefore indicated in 69% of the patients in group A and 100% of the patients in group B. The mean ICU stay was 9 and 32 days for patients in groups A and B respectively. The wound debridement frequency and hospitalization stay were significantly greater in group B (13 vs. 5 debridement and 40 vs. 22 days). Initial antibiosis was test validated in 80% of the patients in group A and 76.5% of the patients in group B. Mortality was 0% in group B and 4.4% in the group A. Conclusion: The positive influence of HBO on the treatment of Fournier’s gangrene can be estimated only from the available data. Despite poorer baseline findings with comparable risk factors, mortality was 0% in the HBO group. The analysis of a larger patient cohort is desirable to increase the significance of the results.

Keywords:
Necrotizing fasciitis, Fournier’s gangrene, Necrotomy, Soft tissue infection, Hyperbaric oxygenation
1.
Voelzke BB, Hagedorn J: Presentation and diagnosis of Fournier Gangrene. Urology 2018; 114: 8–13.
2.
Grabe M, Bjerklund-Johansen TE, Botto H, Wullt B, Cek M, Naber KG, et al: Guidlines of Urological Infections. Arnhem, European Association of Urology (EAU), 2011, pp 76–78.
3.
Sugihara T, Yasunaga H, et al: Impact of surgical intervention timing on the case fatality rate for Fournier’s gangrene: an analysis of 379 cases. BJU Int 2012; 110:E1096–E1100.
4.
Willy C, Rieger H, Vogt D: Hyperbare oxygenation bei nekrotisierenden Weichteilinfektionen: Kontra. Chirurg 2012; 83: 960–972.
5.
Mindrup SR: Hyperbaric oxygen for the treatment of Fourniers-gangrene. J Urol 2005; 173: 1975–1977.
6.
Schmale M, Fichtner A, Pohl C, et al: Hyperbare Oxygenation bei nekrotisierenden Weichteilinfektionen: Pro. Chirurg 2012; 83: 973–979.
7.
Hassan Z, Mullins RF, Friedmann BC, et al: Treating necrotizing fasciitis with or without hyperbaric oxygen therapy. Undersea Hyperb Med 2010; 37: 115–123.
8.
Herenberger K, Brismar K, Folke L, et al: Dosedependent hyperbaric oxygen stimulation of human fibroblast. Wound Rep Reg 1997; 5: 147–150.
9.
Ninikoski J, Heughan C, Hunt TK: Oxygen tension in human wounds. J Surg Res 1972; 12: 77–82.
10.
Ninikoski J: Current concepts of the role of oxygen in wound healing. Ann Chir Gynaecol 2001; 215(suppl): 9–11.
11.
Laor E, Palmer LS, Tolia B, et al: Outcome prediction in patients with Fournier gangrene. J Urol 1995; 154: 89.
12.
Pizzorno R, Bonini F, Donelli A, et al: Hyperbaric oxygen in the treatment of Fournier diseases 1n 11 male patients. J Urol 1997; 158: 837.
13.
Hejase MJ, Simonin JE, Bihrle R, Coogan CL: Genital Fourniers gangrene: experience with 38 patients. Urology 1996; 47: 734.
14.
Korhonen K, Hirn M, Niinikoski J: Hyperbaric oxygen in the treatment of Fournier’s gangrene. Eur J Surg 1998; 164: 251.
15.
Sorensen MD, Krieger JN: Fournier’s Gangrene: epidemiology and outcomes in the general US population. Urol Int 2016; 97: 249–259.
16.
Osburn N, Hapson LA, Holt SK, Gore JL, Wessells H, Voulzke BB: Low-volume versus high-volume centers and management of Founier’s Gangrene in Washington state. J Am Coll Surg 2017; 224: 270–275.
17.
Yilmazlar T, Gulcu B, Isik O, Ozturk E: Microbiological aspects of Fournier’s gangrene. Int J Surg 2017; 40: 135–137.
18.
Furr J, Watts T, Street R, Cross B, Slobodov G, Patel S: Contemporary trends in the inpatient management of Fournier’s gangrene: predictors of length of stay and mortality based on population-based sample. Urology 2017; 102: 79–84.
19.
Czymek R, Kujath P, Bruch HP, Pfeiffer D, Nebrig M, Seehofer D, Guckelberger O: Treatment, outcome and quality of life after Fournier’s gangrene: a multicentre study. Colorectal Dis 2013; 15: 1529–1536.
20.
Tarchouli M, Bounaim A, Essarghini M, Ratbi MB, Belhamidi MS, Bensal A, Zemmouri A, Ali AA, Sair K: Analysis of prognostic factors affecting mortality in Fournier’s gangrene: a study of 72 cases. Can Urol Assoc J 2015; 9: 800–804.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.